Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...
Clinical Trials Arena on MSN5d
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatmentImunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...
Q4 2024 Management View CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ...
Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
Clinical research agreements (CRAs) and developing a regulatory strategy—particularly in connection with the Food and Drug Administration ...
Ainnova has hired an ophthalmologist, who is assisting in drafting the requirements for the clinical trial protocol that the Company's Contract Research Organization (CRO), Fortrea, has requested.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback